– USA, FL – Oragenics, Inc. (NYSE American: OGEN) today announced the appointments of Bruce Cassidy and John Gandolfo to its Board of Directors effective October 4, 2023.
“We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board. Bruce’s deep experience in high-technology global businesses will be invaluable to Oragenics as we grow our portfolio. John’s proven leadership in the life sciences, capital raising and financial management will be critical to our future. We are confident that Bruce and John will provide valuable perspectives as we continue to execute our strategy, pursue our mission to serve patients and enhance value for all Oragenics’ shareholders,” said Board Chairman, Charlie Pope.
About Bruce Cassidy
Mr. Cassidy currently serves on the boards of various companies, including as Chairman of the Board of each of Loop Media, Inc., KeyStar Corp, Arboreta Healthcare, Inc., Selinsky Force, LLC, and The Sarasota Green Group. He was also the founding investor and served on the board of directors of Ohio Legacy Corp. Previously, Mr. Cassidy was the founder and CEO of Excel Mining Systems from 1991 until its sale in 2007 to Orica Mining Services, and from 2008 to 2009, served as the President and CEO of one of its subsidiaries, Minova North & South Americas. He is currently the President of The Concession Golf Club in Sarasota, Florida.
“I am excited to be a part of the next generation of drug and delivery technologies for critical unmet medical needs. The unique platform of formulas and the nasal application of delivering novel therapeutics represents the future of neurological drugs. I look forward to working with the Oragenics Board and the Odyssey team to help steer the new strategy and direction of the Company,” said Bruce Cassidy.
About John Gandolfo
Mr. Gandolfo has more than 30 years of experience as a CFO of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare, and medical device areas. Mr. Gandolfo has had direct responsibility over all financial and treasury functions including capital raising and mergers and acquisitions. Mr. Gandolfo currently serves as CFO of Eyenovia, Inc., a late-stage ophthalmic biopharmaceutical company since January 2018. Before this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Before this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo currently serves on the Board of Directors of Electrocore, Inc. and previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., from 2019 until 2023. Oragenics announced the signing of an asset purchase agreement with Odyssey Health on October 6, 2023.
“Having been involved with the Odyssey team for the past few years I am a strong believer in the technology and the synergies with Oragenics. I am happy to continue my involvement as a member of Oragenics Board,” said John Gandolfo.
Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. is chair of the Compensation Committee, and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University.
About Oragenics
Oragenics, Inc. is a development-stage company focused on nasal delivery of pharmaceutical medications including in neurology, and fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health and the National Research Council of Canada with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
SOURCE: https://www.oragenics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
